Fig. 3: SR9009 inhibited PCS1 by downregulating FOXM1 expression. | Cell Death & Disease

Fig. 3: SR9009 inhibited PCS1 by downregulating FOXM1 expression.

From: SR9009 inhibits lethal prostate cancer subtype 1 by regulating the LXRα/FOXM1 pathway independently of REV-ERBs

Fig. 3

A Heatmap of genes in the FOXM1 pathway after SR9009 or DMSO administration. B GSEA of the FOXM1 pathway after SR9009 or DMSO administration. C Expression of FOXM1 between normal and tumor samples in TCGA-PRAD using the GEPIA database. D Association of FOXM1 expression and disease-free survival using the GEPIA database. E Relative expression of PC3 and 22rv1 compared with RWPE-1-cell lines. F, G qPCR validation of the knockdown of FOXM1 in PC3 and 22RV1 cell lines; n = 3; means ± SDs; ANOVA. H Western blot validation of the knockdown of FOXM1 in PC3 and 22RV1 cell lines. I, J Flow cytometry of cell cycle analysis of siFOXM1 in PC3 and 22RV1 cells after 48 h of transfection; n = 3; means ± SDs; ANOVA. K: CCK-8 assays of the effect of siFOXM1 on cell viability in PC3 (n = 6) and 22RV1 (n = 5) cells; means ± SDs; ANOVA. L Western blot of FOXM1 overexpression validation in PC3 cells. OE overexpression. M SR9009 (20 μM)-induced cytotoxicity (48 h incubation) could be partially rescued by FOXM1 overexpression; n = 4; means ± SDs; unpaired t test. ns not significant; *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001.

Back to article page